Press Releases Revolution Medicines, Inc.

Equities

RVMD

US76155X1000

Real-time Estimate Cboe BZX Other stock markets 02:39:50 2024-05-15 pm EDT			5-day change	1st Jan Change
39.54 ^USD	+5.77%		+3.18%	+37.83%

May. 09	Wedbush Raises Price Target on Revolution Medicines to $46 From $42, Maintains Outperform Rating	MT
May. 08	Revolution Medicines Q1 Net Loss Narrows	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Revolution Medicines : RVMD Corporate Presentation	May. 08	PU
Revolution Medicines Reports First Quarter 2024 Financial Results and Update on Corporate Progress	May. 08	AQ
Revolution Medicines to Report Financial Results for First Quarter 2024 After Market Close on May 8, 2024	May. 01	AQ
Revolution Medicines Announces Publication on the Discovery of and Translational Research for RMC-6236, an Investigational RAS(ON) Multi-Selective Tri-Complex Inhibitor Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins	Apr. 09	AQ
Revolution Medicines Announces Publications on the Discovery and Preclinical Profile of Representative of a New Class of RAS(ON) Multi-Selective Inhibitors Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins	Apr. 08	AQ
Aethon Therapeutics Announces Collaboration with Revolution Medicines to Discover and Develop Novel Aethon Antibody Programs	Apr. 05	AQ
Revolution Medicines to Participate in Upcoming Investor Conferences	Apr. 04	AQ
Revolution Medicines to Deliver Multiple Presentations at the Upcoming American Association for Cancer Research Annual Meeting 2024	Mar. 28	AQ
Revolution Medicines Reports Fourth Quarter and Full Year 2023 Financial Results and Update on Corporate Progress	Feb. 26	AQ
Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2023 After Market Close on February 26, 2024	Feb. 20	AQ
Revolution Medicines to Participate in Upcoming Investor Conferences	Feb. 01	AQ
Revolution Medicines to Present at 42nd Annual J.P. Morgan Healthcare Conference	Jan. 04	AQ
Revolution Medicines Completes Acquisition of EQRx	Nov. 09	AQ
Revolution Medicines and EQRx Stockholders Approve EQRx Acquisition	Nov. 08	AQ
Revolution Medicines : RVMD Corporate Presentation	Nov. 06	PU
Revolution Medicines Reports Third Quarter 2023 Financial Results and Update on Corporate Progress	Nov. 06	AQ
Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Revolution Medicines Stockholders Vote “FOR” Proposed Acquisition of EQRx, Inc.	Nov. 01	AQ
Revolution Medicines to Report Financial Results for Third Quarter 2023 After Market Close on November 6, 2023	23-10-31	AQ
Revolution Medicines Presents Promising Clinical Activity and Safety Data from Phase 1/1b Trial of RMC-6236	23-10-22	AQ
Revolution Medicines : First-in-Human Phase 1/1b Trial of the First-in-Class Bi-Steric mTORC1 Selective Inhibitor RMC-5552 in Patients with Advanced Solid Tumors	23-10-14	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Revolution Medicines, Inc.

Equities

RVMD

US76155X1000

Press Releases

Filters